J
Julie M. Vose
Researcher at University of Nebraska Medical Center
Publications - 569
Citations - 51589
Julie M. Vose is an academic researcher from University of Nebraska Medical Center. The author has contributed to research in topics: Transplantation & Lymphoma. The author has an hindex of 97, co-authored 541 publications receiving 46915 citations. Previous affiliations of Julie M. Vose include Memorial Hospital of South Bend.
Papers
More filters
Journal ArticleDOI
Abstract 6396: BET inhibition alleviates T-cell dysfunction in chronic lymphocytic leukemia
Audrey L. Smith,Alexandria P Eiken,Sydney A Skupa,Christopher D'Angelo,Avyakta Kallam,Matthew A. Lunning,Gregory Bociek,Julie M. Vose,Ben Powell,Gideon Bollag,Dalia El-Gamal +10 more
TL;DR: Smith et al. as discussed by the authors proposed a pan-Bordomain and extra-terminal (BET) inhibitor, OPN-51107 (OPN5), for chronic lymphocytic leukemia (CLL) treatment.
Journal ArticleDOI
Understanding the Treatment Preferences of Adults with Cancer
Prajwal Dhakal,Christopher S. Wichman,Bunny Pozehl,Meaghann S. Weaver,Alfred L. Fisher,Julie M. Vose,Gregory Bociek,Vijaya Raj Bhatt +7 more
TL;DR: The Therapy Preference Scale (TPS) as discussed by the authors is a self-reported questionnaire that measures patients' rating of importance of safety and quality of life, effectiveness of cancer treatment, and other treatment characteristics on an ordinal scale of 1-10.
Journal ArticleDOI
A novel MYC-non-IG fusion in refractory diffuse large B-cell lymphoma.
Cheng Wang,Pamela A. Althof,Chengfeng Bi,Weiwei Zhang,Alyssa Bouska,Tian Tian,Xuan Zhang,Nanxi Jiang,Guohua Yu,Hongxia Cheng,Javeed Iqbal,Julie M. Vose,Jennifer N. Sanmann,Kai Fu +13 more
Journal ArticleDOI
Lenalidomide maintenance following high‐dose therapy and autologous haematopoietic stem cell transplantation in chemo‐resistant or high‐risk non‐Hodgkin lymphoma: A phase I/II study
Julie M. Vose,Siddhartha Ganguly,Philip J. Bierman,Robert G. Bociek,Matthew A. Lunning,Liz Lyden,Jane L. Meza,Paolo Caimi,James O. Armitage +8 more
TL;DR: In this article , a phase I/II, single-arm, open-label study, 59 patients with high-risk relapsed non-Hodgkin lymphoma received pretransplant BEAM chemotherapy and autologous haematopoietic stem cell transplantation (ASCT) followed by 12 months of maintenance lenalidomide once daily on days 1-21 (28 days) beginning at post-transplantation Day 100.